Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

people ride a downhill dip on a roller coaster
Dividend Stocks

3 TSX Stocks to Own if Volatility Sticks Around

These three TSX stocks aim to stay resilient amid volatility by leaning on essentials, recurring cash flow, and disciplined execution.

Read more »

stock chart
Stock Market

2 TSX Stocks Worth Picking Up the Next Time the Market Dips

If another market dip were to come our way, these are two stocks I would be adding to.

Read more »

holding coins in hand for the future
Dividend Stocks

2 Dividend Stocks Worth Holding for the Next 7 Years

These companies have long track records of delivering dividend growth.

Read more »

senior man and woman stretch their legs on yoga mats outside
Dividend Stocks

How to Make Your Retirement Savings Last a Full 30 Years

Canadian Natural Resources stock could be the retirement income anchor you need. Here is how to make your savings last…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, April 24

With the TSX appearing on track to snap its four-week winning streak, investors could continue watching how volatile oil prices…

Read more »

a person watches stock market trades
Stocks for Beginners

Why Smart Canadian Investors Are Watching These 3 Stocks Right Now

These three TSX names are on investors’ watchlists because each has a real catalyst, real growth, and just enough proof…

Read more »

four people hold happy emoji masks
Dividend Stocks

Love Income Stocks? This High-Yield Alternative to Telus Might be Worth a Look

Alaris Equity Partners Income Trust offers a high-yield of 6.6%, with the benefits of diversification, strong returns, and growth.

Read more »

hand stacks coins
Dividend Stocks

3 Canadian Dividend Stocks Whose Passive Income Just Keeps Climbing

Here's a group of Canadian dividend stocks investors can look to buying on dips for growing passive income.

Read more »